Hanmi Pharm Q2 Operating Profit 10.6 Billion KRW... 54.1% Decrease YoY

[Asia Economy Reporter Cho Hyun-ui] Hanmi Pharm announced on the 29th that its consolidated operating profit for the second quarter of this year was tentatively estimated at 10.6 billion KRW, a 54.1% decrease compared to the same period last year. Sales amounted to 243.4 billion KRW, down 10% from the same period last year. Net profit fell 71.7% to 5.8 billion KRW.

Hanmi Pharm explained that its standalone performance recorded sales of 215.6 billion KRW and an operating profit of 18.8 billion KRW, a 7% increase year-on-year, but the overall results were affected by the poor performance of Beijing Hanmi Pharm, which was hit by the COVID-19 pandemic.

Beijing Hanmi Pharm recorded sales of 27.1 billion KRW in the second quarter, a 52% decline compared to the previous year due to the worsening market conditions in China, and both operating profit and net profit turned to losses.

However, the company emphasized the remarkable growth of its self-developed products such as the hypertension treatment 'AmozalTan Family' (AmozalTan, AmozalTan Q, AmozalTan Plus), the chewable erectile dysfunction treatment 'Palpal Chewable Tablets', and the reflux esophagitis treatment 'Esomazol'. In fact, the dyslipidemia combination drug 'Rosuzet' achieved sales of 24.1 billion KRW, a 21.6% increase compared to the same period last year.

This content was produced with the assistance of AI translation services.